Ensayos clinicos

1.641 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

INTERVENTIONALInicio: 15 de oct de 2025ID: NCT07165028

ReclutandoFase 3ClinicalTrials.gov

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

INTERVENTIONALInicio: 15 de may de 2025ID: NCT06972459

ReclutandoFase 3ClinicalTrials.gov

PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

INTERVENTIONALInicio: 29 de sept de 2025ID: NCT07144280

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

INTERVENTIONALInicio: 24 de jul de 2024ID: NCT06459180

ReclutandoFase 3ClinicalTrials.gov

Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations

INTERVENTIONALInicio: 9 de feb de 2024ID: NCT06151574

ReclutandoClinicalTrials.gov

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS). A Multicenter Randomized Phase III Trial (OPBC-03/ SAKK 23/16 /IBCSG 57-18 / ABCSG-53 / GBG-101)

INTERVENTIONALInicio: 7 de ago de 2018ID: NCT03513614

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function

INTERVENTIONALInicio: 12 de abr de 2024ID: NCT06307652

ReclutandoFase 4ClinicalTrials.gov

Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy.

INTERVENTIONALInicio: 6 de oct de 2017ID: NCT03500133

ReclutandoFase 3ClinicalTrials.gov

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

INTERVENTIONALInicio: 4 de abr de 2025ID: NCT06801834

ReclutandoFase 1ClinicalTrials.gov

A Phase 1, First-time-in-human, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), Healthy Participants of Chinese and Japanese Descent (Part C) and Participants With Interstitial Lung Disease Associated With Connective Tissue Disease (Part D)

INTERVENTIONALInicio: 2 de sept de 2024ID: NCT06576271

ReclutandoClinicalTrials.gov

Advanced Wireless Sensors for Neonatal Care in the Delivery Room: the AWARD Prospective Multicenter International Study

INTERVENTIONALInicio: 8 de abr de 2025ID: NCT06693817

ReclutandoFase 3ClinicalTrials.gov

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

INTERVENTIONALInicio: 24 de ene de 2026ID: NCT07357415

ReclutandoFase 3ClinicalTrials.gov

TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.

INTERVENTIONALInicio: 21 de mar de 2025ID: NCT06726265

ReclutandoClinicalTrials.gov

Latin American Lifestyle Intervention Initiative to Reduce the Risk and Prevent Cognitive Impairment.

INTERVENTIONALInicio: 1 de sept de 2021ID: NCT06492967

ReclutandoFase 2ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

INTERVENTIONALInicio: 16 de may de 2025ID: NCT06947993

ReclutandoFase 3ClinicalTrials.gov

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

INTERVENTIONALInicio: 12 de jul de 2023ID: NCT05819866

ReclutandoFase 3ClinicalTrials.gov

EASi-HF Preserved - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) ≥40%

INTERVENTIONALInicio: 17 de jun de 2024ID: NCT06424288

ReclutandoFase 3ClinicalTrials.gov

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)

INTERVENTIONALInicio: 1 de ago de 2025ID: NCT07044336

ReclutandoClinicalTrials.gov

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

OBSERVATIONALInicio: 12 de may de 2025ID: NCT06924021

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

INTERVENTIONALInicio: 22 de ene de 2024ID: NCT06208150